Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
09 sept. 2024 08h30 HE
|
Xenon Pharmaceuticals Inc.
Three presentations highlighting long-term data and improved quality of life outcomes in adults with focal onset seizures VANCOUVER, British Columbia and BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) --...
Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
12 août 2024 08h30 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering,...
Xenon Reports Q2 2024 Financial Results and Business Update
08 août 2024 16h01 HE
|
Xenon Pharmaceuticals Inc.
— Phase 3 epilepsy program progressing with X-TOLE2 topline FOS data anticipated in H2 2025— MDD program on track with Phase 3 study expected to initiate in H2 2024— Multiple Kv7 and Nav1.7 candidates...
Xenon to Report Q2 2024 Financial Results on August 8, 2024
01 août 2024 16h01 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and...
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
05 juin 2024 16h01 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, June 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will...
Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
28 mai 2024 08h30 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting...
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
09 mai 2024 16h01 HE
|
Xenon Pharmaceuticals Inc.
Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful “end-of-Phase 2” interactions with FDA in MDD; Phase...
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
08 mai 2024 16h01 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will...
Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
07 mai 2024 16h01 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will...
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
02 mai 2024 16h01 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, May 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced it will report its first...